Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?

References

• Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795.
   PubMed Web of Science ®Google Scholar
• Li S, Mason CE, Melnick A. Genetic and epigenetic heterogeneity in acute myeloid leukemia. Curr Opin Genet Dev. 2016;36:100–106.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–427.
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Chan SM, Daver NG, et al. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol. 2019;94(7):803–811.
   PubMed Web of Science ®Google Scholar
• Döhner H, Gaidzik VI. Impact of genetic features on treatment decisions in AML. Hematology (Am Soc Hematol Educ Program). 2011;2011:36–42.
   PubMedGoogle Scholar
• Smith FO. Personalized medicine for AML? Blood. 2010;116:2622–2623.
   PubMedGoogle Scholar
• Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–2074.
   PubMed Web of Science ®Google Scholar
• Corces-Zimmerman MR, Hong WJ, Weissman IL, et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A. 2014;111:2548–2553.
   PubMed Web of Science ®Google Scholar
• Bruserud Ø, Aasebø E, Hernandez-Valladares M, et al. Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. Expert Opin Drug Discov. 2017;12:1053–1065.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875–1891.
   PubMed Web of Science ®Google Scholar
• Keung YK, Beaty M, Powell BL, et al. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia- retrospective study and review of literature. Leuk Res. 2004;28:579–586.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Konishi I. Successful treatment with imatinib mesylate for Philadelphia chromosome- positive refractory acute myeloid leukemia. Rinsho Ketsueki. 2003;44:254–256.
   PubMedGoogle Scholar
• Jentsch-Ullrich K, Pelz AF, Braun H, et al. Complete molecular remission in a patient with Philadelphia chromosome positive acute myeloid leukemia after conventional therapy and imatinib. Haematologica. 2004;89(5):ECR15.
   PubMedGoogle Scholar
• Viniou NA, Vassilakopoulos TP, Giakoumi X, et al. Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia. Eur J Haematol. 2004;72:58–60.
   PubMed Web of Science ®Google Scholar
• Ito K, Tominaga K, Suzuki T, et al. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia. Int J Hematol. 2005;81:242–245.
   PubMed Web of Science ®Google Scholar
• Grafone T, Palmisano M, Nicci C, et al. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev. 2012;6:e8.
   PubMedGoogle Scholar
• Megías-Vericat JE, Ballesta-López O, Barragán E, et al. Tyrosine kinase inhibitors for acute myeloid leukemia: a step toward disease control? Blood Rev. 2020 Mar 2;100675. DOI:10.1016/j.blre.2020.100675. Online ahead of print.
   Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377:454–464.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2019 Jul;20(7):e346]. Lancet Oncol. 2019;20(7):984‐997.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Montesinos P, Selleslag D, et al. Design of the randomized, phase III, QUAZAR AML maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncol. 2016;12(3):293–302.
   PubMed Web of Science ®Google Scholar
• Wei A, Döhner H, Pocock C, et al. The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (Oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission [Abstract]. Blood. 2019;134(S2):LBA–3.
   Google Scholar
• Platt MY, Fathi AT, Borger DR, et al. Detection of dual IDH1 and IDH2 mutations by targeted next-generation sequencing in acute myeloid leukemia and myelodysplastic syndromes. J Mol Diagn. 2015;17(6):661–668.
   PubMedGoogle Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398.
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Ballesta-López O, Barragán E, et al. IDH1-mutated relapsed or refractory AML: current challenges and future prospects. Blood Lymphat Cancer. 2019;9:19–32.
   PubMed Web of Science ®Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–184.
   PubMed Web of Science ®Google Scholar
• Dinardo C, Takahashi K, Kadia T, et al. A phase 1B/2 clinical study of targeted IDH1 inhibition with ivosidenib, in combination with the bcl-2 inhibitor venetoclax, for patients with IDH1-mutated (MIDH1) myeloid malignancies [abstract]. Haematologica. 2019:266091.
   Google Scholar
• Cathelin S, Sharon D, Subedi A, et al. Combination of enasidenib and venetoclax shows superior anti-leukemic activity against IDH2 mutated AML in patient-derived xenograft models [Abstract]. Blood. 2018;132:562.
   Web of Science ®Google Scholar
• Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145.
   PubMed Web of Science ®Google Scholar
• Döhner H, Dolnik A, Tang L, et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018;32(12):2546–2557.
   PubMed Web of Science ®Google Scholar
• Ali D, Jönsson-Videsäter K, Deneberg SB, et al. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. Eur J Haematol. 2011;86(3):206–215.
   PubMed Web of Science ®Google Scholar
• Sallman D, DeZern A, Steensma DP, et al. Phase 1b/2 combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [Abstract]. Blood. 2018;132(S1):3091.
   Google Scholar
• Tisato V, Voltan R, Gonelli A, et al. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. J Hematol Oncol. 2017;10(1):133.
   PubMedGoogle Scholar
• Montesinos P, Beckermann BM, Catalani O, et al. MIRROS: a randomized, placebo-controlled, phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. Future Oncol. 2020;16(13):807–815.
   PubMed Web of Science ®Google Scholar
• Leung GMK, Zhang C, Ng NKL, et al. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations. Am J Hematol. 2019;94(6):650–657.
   PubMed Web of Science ®Google Scholar
• Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a metaanalysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;5:986–996.
   Google Scholar
• Megías-Vericat JE, Martínez-Cuadrón D, Sanz MÁ, et al. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. Expert Rev Clin Pharmacol. 2019;12(3):197–218.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–1516.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379–389.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692.
   PubMed Web of Science ®Google Scholar
• Yadav B, Pemovska T, Szwajda A, et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep. 2014;4:5193.
   PubMed Web of Science ®Google Scholar
• Swords RT, Azzam D, Al-Ali H, et al. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: a pilot study. Leuk Res. 2018;64:34–41.
   PubMed Web of Science ®Google Scholar
• Pemovska T, Kontro M, Yadav B, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013;3:1416–1429.
   PubMed Web of Science ®Google Scholar
• Kurtz SE, Eide CA, Kaempf A, et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A. 2017;114(36):E7554–E7563.
   PubMed Web of Science ®Google Scholar
• Staib P, Staltmeier E, Neurohr K, et al. Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. Br J Haematol. 2005;128:783–791.
   PubMed Web of Science ®Google Scholar
• Aziz H, Ping CY, Alias H, et al. Gene mutations as emerging biomarkers and therapeutic targets for relapsed acute myeloid leukemia. Front Pharmacol. 2017;8:897.
   PubMed Web of Science ®Google Scholar
• Bennett TA, Montesinos P, Moscardo F, et al. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. Clin Lymphoma Myeloma Leuk. 2014;14:305–318.
   PubMed Web of Science ®Google Scholar
• Martínez-Cuadrón D, Gil C, Serrano J, et al. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. Leuk Res. 2019;76:1–10.
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Martínez-Cuadrón D, Martínez López J, et al. Differences in ex-vivo chemosensitivity to anthracyclines in first line acute myeloid leukemia. Mediterr J Hematol Infect Dis. 2019 1; 11(1):e2019016.
   PubMedGoogle Scholar
• Smith BD, Warner SL, Whatcott C, et al. An alvocidib-containing regimen is highly effective in AML patients through a mechanism dependent on MCL1 expression and function [abstract]. J Clin Oncol. 2015;33(15):7062.
   Web of Science ®Google Scholar
• Zeidner JF, Lin TL, Vigil CE, et al. A biomarker-guided phase II study of alvocidib followed by cytarabine and mitoxantrone in MCL-1 dependent relapsed/refractory acute myeloid leukemia (AML) [Abstract]. Blood. 2018;132(S1):30.
   Google Scholar
• Gréen H, Falk IJ, Lotfi K, et al. Association of ABCB1 polymorphisms with survival and in vitro cytotoxicity in de novo acute myeloid leukemia with normal karyotype. Pharmacogenomics J. 2012;12(2):111–118.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Lonetti A, Candoni A, et al. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with gemtuzumab-ozogamicin and fludarabine, cytarabine and idarubicin. Pharmacogenomics J. 2012;13(4):335–341.
   PubMed Web of Science ®Google Scholar
• Mahlknecht U, Dransfeld CL, Bulut N, et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia. 2009;23(10):1929–1932.
   PubMed Web of Science ®Google Scholar
• Falk IJ, Fyrberg A, Paul E, et al. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5ʹ-nucleotidase. Am J Hematol. 2013;88(12):1001–1006.
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Montesinos P, Herrero MJ, et al. Pharmacogenomics and the treatment of acute myeloid leukemia. Pharmacogenomics. 2016;17(11):1245–1272.
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Martínez-Cuadrón D, Herrero MJ, et al. Pharmacogenetics of metabolic genes of anthracyclines in acute myeloid leukemia. Curr Drug Metab. 2018;19(1):55–74.
   PubMed Web of Science ®Google Scholar
• Lsayed AH, Cao X, Crews KR, et al. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics. 2018;19(14):1101–1110.
   PubMed Web of Science ®Google Scholar
• Zhu KW, Chen P, Zhang DY, et al. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML). J Transl Med. 2018;16(1):90.
   PubMedGoogle Scholar
• Donnette M, Solas C, Giocanti M, et al. Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: application to pharmacokinetics-pharmacogenetics pilot study in AML patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1126–1127:121770.
   PubMed Web of Science ®Google Scholar
• Gamazon ER, Lamba JK, Pounds S, et al. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood. 2013;121:4366–4376.
   PubMed Web of Science ®Google Scholar
• Bargal SA, Rafiee R, Crews KR, et al. Genome-wide association analysis identifies SNPs predictive of in vitro leukemic cell sensitivity to cytarabine in pediatric AML. Oncotarget. 2018;9(79):34859–34875.
   PubMedGoogle Scholar
• Phillips CL, Lane A, Gerbing RB, et al. Genomic variants of cytarabine sensitivity associated with treatment-related mortality in pediatric AML: a report from the children’s oncology group. Clin Cancer Res. 2020;26:2891–2897.
   PubMed Web of Science ®Google Scholar
• Chen L, Manautou JE, Rasmussen TP, et al. Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2. Acta Pharm Sin B. 2019;9(4):659–674.
   PubMed Web of Science ®Google Scholar
• Kulski JK. Next-generation sequencing — an overview of the history, tools, and “omic” applications, next generation sequencing - advances, applications and challenges. IntechOpen; 2016.
   Google Scholar
• Kuo FC, Mar BG, Lindsley RC, et al. The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. Blood. 2017;130(4):433–439.
   PubMed Web of Science ®Google Scholar
• Bacher U, Shumilov E, Flach J, et al. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. Blood Cancer J. 2018;8(11):113.
   PubMedGoogle Scholar
• Visani G, Loscocco F, Isidori A, et al. Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome. Expert Rev Hematol. 2018;11(6):455–461.
   PubMed Web of Science ®Google Scholar
• Isidori A, Loscocco F, Curti A, et al. Genomic profiling and predicting treatment response in acute myeloid leukemia. Pharmacogenomics. 2019;20(7):467–470.
   PubMed Web of Science ®Google Scholar
• Visani G, Ferrara F, Di Raimondo F, et al. Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: final result of a phase II study. Leuk Res. 2017;62:77–83.
   PubMed Web of Science ®Google Scholar